Background. Yoganidra is a systematic method of promoting a state of complete physical, mental, and emotional relaxation. It is a safe, inexpensive, and very effective method of management of hypertension when used along with standard pharmacological therapy. This study aims to assess the effect of yoganidra on blood pressure (both systolic blood pressure (SBP) and diastolic blood pressure (DBP)), Hs-CRP, and lipid profile of hypertensive subjects at the time of enrollment (subjects that are hypertensive at the time of enrollment). Methods. Both treated and untreated subjects (n = 74) with hypertension (blood pressure ≥140/90 mmHg) and age between 35 and 70 years were included in this study after obtaining ICMR-NIN-IEC approval and written informed consent from all subjects. Subjects with critical illness and/or psychological disturbances were excluded from this study. The subjects in the experimental group (n = 31) practiced yoganidra for 45 minutes daily for 12 weeks under strict supervision. There was no intervention in the control group (n = 43). Weekly blood pressure was recorded in the experimental group, whereas it was performed at baseline and at endpoint for control groups. Hs-CRP and lipid profile were estimated at baseline and endpoint for both the groups. Results. A significant reduction in mean SBP from 142.9 mm Hg (SD ± 16.46) to 118.68 mm Hg (SD ± 9.21;
p
value 0.0001) and DBP from 89.84 mm Hg (SD ± 10.42) to 77.03 mm Hg (SD ± 6.47:
p
value 0.0001) was observed among the experimental group after 12 weeks of yoganidra practice when compared with the control group. A significant reduction in mean Hs-CRP (2.21 ± 1.49 to 1.06 ± 0.82 mg/L,
p
< 0.001
∗
∗
∗
) was observed among the experimental group. There were no significant differences between triglycerides and total cholesterol levels, whereas LDL-C and HDL-C showed a trend of improvement in the experimental group after intervention. Conclusions. In this pilot study, we observed a significant reduction in blood pressure and Hs-CRP in the yoganidra group compared with the control group. There were no significant side effects observed in the intervention group during the study period.
Objective: The objective of the present study was to evaluate the anti-diabetic activity of methanolic extract from the leaves of Rotula aquatica lour in Alloxan-induced diabetic rats. Materials and Methods: Diabetes was induced in rat by injection of Alloxan (120mg/kg, i.p.). Diabetic rats were divided into different groups and methanolic leaves extract of Rotula aquatica lour (RA-ME) was administered at dose ranges of 100-400mg/kg, p.o for 21 days. Control group received normal saline (0.9%) for 21 days. Glibenclamide (5mg/kg, p.o) was used as standard drug. Blood samples were collected from all the groups and analyzed for serum glucose and lipid levels such as total cholesterol (TC), triglyceride (TG), proteins (TP). RA-ME was also tested for oral glucose tolerance test (OGTT) in normal fasted rats. Results: RA-ME (400mg/kg, p.o) showed a significant (P<0.01) reduction of serum glucose level in Alloxan-induced diabetic mice as compared with diabetic control. RA-ME (200 and 400mg/kg) also showed a significant reduction in serum TC, TG, and TP levels in Alloxan-induced diabetic rats. RA-ME (200 and 400mg/kg, p.o) significantly (P<0.01) increased the glucose tolerance in OGTT. Conclusion: The results obtained from the present study revealed the potential anti-diabetic activity of methanolic extract from the leaves of Rotula aquatica lour.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.